Pathology of hepatic iron overload

Seminars in Liver Disease

Volumn 31, Issue 3, 2011, Pages 260-271

  Deugnier, Yves ^a,b,c   Turlin, Bruno ^b,c,d  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c INSERM   (France)

^d RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

hemochromatosis; iron overload; Liver pathology

Indexed keywords

IRON;

ACERULOPLASMINEMIA; ALCOHOL LIVER DISEASE; ARTICLE; CELLULAR DISTRIBUTION; CHRONIC LIVER DISEASE; CONCENTRATION (PARAMETERS); DYSMETABOLIC IRON OVERLOAD SYNDROME; ERYTHROPOIESIS; FERROPORTIN DISEASE; GENETIC DISORDER; GENETIC IRON OVERLOAD; GENETIC SCREENING; GENOTYPE; HEMOCHROMATOSIS; HEMOLYTIC ANEMIA; HEPATIC IRON CONCENTRATION; HEPATIC IRON OVERLOAD; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; INEFFECTIVE ERYTHROPOIESIS; INFLAMMATION; IRON OVERLOAD; LIVER BIOPSY; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER INJURY; MESENCHYMAL IRON OVERLOAD; MIXED IRON OVERLOAD; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PARENCHYMAL IRON OVERLOAD; PATHOLOGIST; PORPHYRIA CUTANEA TARDA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; SYMPTOM; VIRUS HEPATITIS; WILSON DISEASE;

BIOPSY; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON; IRON OVERLOAD; LIVER; LIVER DISEASES; MEMBRANE PROTEINS;

EID: 80052657110     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0031-1286057     Document Type: Article

References (87)

1. Turlin B, Deugnier Y. Evaluation and interpretation of iron in the liver. Semin Diagn Pathol 1998 15 4 237-245 (Pubitemid 28536757)
2. Turlin B, Loreal O, Moirand R, Brissot P, Deugnier Y, Ramee M P. [Histochemical detection of hepatic iron. A comparative study of four stains]. Ann Pathol 1992 12 6 371-373 (Pubitemid 23079922)
3. Brissot P, Bourel M, Herry D et al. Assessment of liver iron content in 271 patients: a reevaluation of direct and indirect methods. Gastroenterology 1981 80 3 557-565 (Pubitemid 11183958)
4. Imbert-Bismut F, Charlotte F, Turlin B et al. Low hepatic iron concentration: evaluation of two complementary methods, colorimetric assay and iron histological scoring. J Clin Pathol 1999 52 6 430-434 (Pubitemid 29281760)
5. Scheuer P J., Williams R, Muir A R. Hepatic pathology in relatives of patients with haemochromatosis. J Pathol Bacteriol 1962 84 53-64
6. Bothwell T H., Abrahams C, Bradlow B A., Charlton R W. Idiopathic and Bantu hemochromatosis. Comparative histological study. Arch Pathol 1965 79 163-168
7. Conn H O., Strauss R H., Conn M B. Estimation of hepatic hemosiderin by gross inspection of iron-stained histologic sections. Yale J Biol Med 1972 45 2 133-138
8. Deugnier Y M., Loréal O, Turlin B et al. Liver pathology in genetic hemochromatosis: a review of 135 homozygous cases and their bioclinical correlations. Gastroenterology 1992 102 6 2050-2059
9. Deugnier Y M., Turlin B, Powell L W. et al. Differentiation between heterozygotes and homozygotes in genetic hemochromatosis by means of a histological hepatic iron index: a study of 192 cases. Hepatology 1993 17 1 30-34 (Pubitemid 23027380)
10. Rowe J W., Wands J R., Mezey E et al. Familial hemochromatosis: characteristics of the precirrhotic stage in a large kindred. Medicine (Baltimore) 1977 56 3 197-211 (Pubitemid 8111453)
11. Searle J, Kerr J, Halliday J W., Powell L W. Iron storage disease. In: MacSweeen R Anthony P Scheuer P eds. Pathology of the Liver. London Churchill Livingstone 1988 181-201
12. Turlin B, Deugnier Y. Histological assessment of liver siderosis. J Clin Pathol 1997 50 11 971
13. Deugnier Y, Margules S, Brissot P et al. Comparative study between biochemical and histological methods and image analysis in liver iron overload. J Clin Pathol 1982 35 1 45-51 (Pubitemid 12180849)
14. Olynyk J, Hall P, Sallie R, Reed W, Shilkin K, Mackinnon M. Computerized measurement of iron in liver biopsies: a comparison with biochemical iron measurement. Hepatology 1990 12 1 26-30 (Pubitemid 20234004)
15. Olynyk J K., O'Neill R, Britton R S., Bacon B R. Determination of hepatic iron concentration in fresh and paraffin-embedded tissue: diagnostic implications. Gastroenterology 1994 106 3 674-677 (Pubitemid 24064334)
16. Deugnier Y, Turlin B, le Quilleuc D et al. A reappraisal of hepatic siderosis in patients with end-stage cirrhosis: practical implications for the diagnosis of hemochromatosis. Am J Surg Pathol 1997 21 6 669-675 (Pubitemid 27265755)
17. Ludwig J, Hashimoto E, Porayko M K., Moyer T P., Baldus W P. Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterology 1997 112 3 882-888 (Pubitemid 27113814)
18. Villeneuve J P., Bilodeau M, Lepage R, Côté J, Lefebvre M. Variability in hepatic iron concentration measurement from needle-biopsy specimens. J Hepatol 1996 25 2 172-177 (Pubitemid 26276629)
19. Gandon Y, Olivié D, Guyader D et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 2004 363 9406 357-362 (Pubitemid 38169542)
20. Pietrangelo A. Non-invasive assessment of hepatic iron overload: are we finally there? J Hepatol 2005 42 1 153-154
21. Brunt E M., Olynyk J K., Britton R S., Janney C G., Di Bisceglie A M., Bacon B R. Histological evaluation of iron in liver biopsies: relationship to HFE mutations. Am J Gastroenterol 2000 95 7 1788-1793 (Pubitemid 30485020)
22. Brunt E M. Pathology of hepatic iron overload. Semin Liver Dis 2005 25 4 392-401 (Pubitemid 41741256)
23. Bridle K R., Crawford D H., Fletcher L M., Smith J L., Powell L W., Ramm G A. Evidence for a sub-morphological inflammatory process in the liver in haemochromatosis. J Hepatol 2003 38 4 426-433 (Pubitemid 36399244)
24. Fracanzani A L., Fargion S, Romano R et al. Portal hypertension and iron depletion in patients with genetic hemochromatosis. Hepatology 1995 22 4 Pt 1 1127-1131
25. Adams P C. Is there a threshold of hepatic iron concentration that leads to cirrhosis in C282Y hemochromatosis? Am J Gastroenterol 2001 96 2 567-569
26. Powell L W., Dixon J L., Ramm G A. et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 2006 166 3 294-301 (Pubitemid 43244317)
27. Falize L, Guillygomarc'h A, Perrin M et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006 44 2 472-477 (Pubitemid 44214887)
28. Guyader D, Jacquelinet C, Moirand R et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 1998 115 4 929-936 (Pubitemid 28452941)
29. George D K., Ramm G A., Walker N I., Powell L W., Crawford D H. Elevated serum type IV collagen: a sensitive indicator of the presence of cirrhosis in haemochromatosis. J Hepatol 1999 31 1 47-52 (Pubitemid 29287608)
30. Crawford D H., Murphy T L., Ramm L E. et al. Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis. Hepatology 2009 49 2 418-425
31. Morrison E D., Brandhagen D J., Phatak P D. et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med 2003 138 8 627-633
32. Beaton M, Guyader D, Deugnier Y, Moirand R, Chakrabarti S, Adams P. Noninvasive prediction of cirrhosis in C282Y-linked hemochromatosis. Hepatology 2002 36 3 673-678 (Pubitemid 34977178)
33. Adhoute X, Foucher J, Laharie D et al. Diagnosis of liver fibrosis using FibroScan and other noninvasive methods in patients with hemochromatosis: a prospective study. Gastroenterol Clin Biol 2008 32 2 180-187 (Pubitemid 351635694)
34. Kowdley K V. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004 127 5, Suppl 1 S79-S86 (Pubitemid 39423373)
35. Bradbear R A., Bain C, Siskind V et al. Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. J Natl Cancer Inst 1985 75 1 81-84 (Pubitemid 15005959)
36. Fracanzani A L., Conte D, Fraquelli M et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 2001 33 3 647-651 (Pubitemid 32185227)
37. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch H J., Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985 313 20 1256-1262 (Pubitemid 16217048)
38. Deugnier Y M., Guyader D, Crantock L et al. Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases. Gastroenterology 1993 104 1 228-234 (Pubitemid 23040027)
39. Morcos M, Dubois S, Bralet M P., Belghiti J, Degott C, Terris B. Primary liver carcinoma in genetic hemochromatosis reveals a broad histologic spectrum. Am J Clin Pathol 2001 116 5 738-743 (Pubitemid 34453216)
40. Deugnier Y M., Charalambous P, Le Quilleuc D et al. Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a study of 185 patients. Hepatology 1993 18 6 1363-1369 (Pubitemid 23348423)
41. Blanc J F., Bernard P H., Carles J, Le Bail B, Balabaud C, Bioulac-Sage P. Cholangiocarcinoma arising in Von Meyenburg complex associated with hepatocellular carcinoma in genetic haemochromatosis. Eur J Gastroenterol Hepatol 2000 12 2 233-237 (Pubitemid 30166691)
42. Pietrangelo A. The ferroportin disease. Blood Cells Mol Dis 2004 32 1 131-138 (Pubitemid 38147710)
43. Island M L., Jouanolle A M., Mosser A et al. A new mutation in the hepcidin promoter impairs its BMP response and contributes to a severe phenotype in HFE related hemochromatosis. Haematologica 2009 94 5 720-724
44. Milet J, Dehais V, Bourgain C et al. Common variants in the BMP2, BMP4, and HJV genes of the hepcidin regulation pathway modulate HFE hemochromatosis penetrance. Am J Hum Genet 2007 81 4 799-807 (Pubitemid 47603057)
45. Nahon P, Sutton A, Pessayre D et al. Do genetic variations in antioxidant enzymes influence the course of hereditary hemochromatosis? Antioxid Redox Signal 2011 15 1 31-38
46. Le Lan C, Mosser A, Ropert M et al. Sex and acquired cofactors determine phenotypes of ferroportin disease. Gastroenterology 2011 140 4 1199-1207 e1-e2
47. Rosmorduc O, Wendum D, Arrivé L et al. Phenotypic expression of ferroportin disease in a family with the N144H mutation. Gastroenterol Clin Biol 2008 32 3 321-327
48. Miyajima H, Takahashi Y, Kono S. Aceruloplasminemia, an inherited disorder of iron metabolism. Biometals 2003 16 1 205-213 (Pubitemid 36140230)
49. Kono S, Suzuki H, Takahashi K et al. Hepatic iron overload associated with a decreased serum ceruloplasmin level in a novel clinical type of aceruloplasminemia. Gastroenterology 2006 131 1 240-245 (Pubitemid 44015751)
50. Beutler E, Gelbart T, Lee P, Trevino R, Fernandez M A., Fairbanks V F. Molecular characterization of a case of atransferrinemia. Blood 2000 96 13 4071-4074
51. Gordeuk V R. African iron overload. Semin Hematol 2002 39 4 263-269 (Pubitemid 35192639)
52. Gordeuk V, Mukiibi J, Hasstedt S J. et al. Iron overload in Africa. Interaction between a gene and dietary iron content. N Engl J Med 1992 326 2 95-100
53. Deugnier Y, Loréal O, Carré F et al. Increased body iron stores in elite road cyclists. Med Sci Sports Exerc 2002 34 5 876-880 (Pubitemid 34465376)
54. Deugnier Y, Brissot P, Loréal O. Iron and the liver: update 2008. J Hepatol 2008 48 Suppl 1 S113-S123
55. Nahon P, Ganne-Carrié N, Trinchet J C., Beaugrand M. Hepatic iron overload and risk of hepatocellular carcinoma in cirrhosis. Gastroenterol Clin Biol 2010 34 1 1-7
56. Jakobovits A W., Morgan M Y., Sherlock S. Hepatic siderosis in alcoholics. Dig Dis Sci 1979 24 4 305-310 (Pubitemid 9170071)
57. Harrison-Findik D D. Role of alcohol in the regulation of iron metabolism. World J Gastroenterol 2007 13 37 4925-4930 (Pubitemid 47496823)
58. Brunt E M. Pathology of nonalcoholic steatohepatitis. Hepatol Res 2005 33 2 68-71 (Pubitemid 41799777)
59. Valenti L, Fracanzani A L., Bugianesi E et al. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2010 138 3 905-912
60. Nelson J E., Wilson L, Brunt E M. et al, Nonalcoholic Steatohepatitis Clinical Research Network. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology 2011 53 2 448-457
61. Mendler M H., Turlin B, Moirand R et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999 117 5 1155-1163 (Pubitemid 29512675)
62. Moirand R, Mortaji A M., Loréal O, Paillard F, Brissot P, Deugnier Y. A new syndrome of liver iron overload with normal transferrin saturation. Lancet 1997 349 9045 95-97 (Pubitemid 27023427)
63. Turlin B, Mendler M H., Moirand R, Guyader D, Guillygomarc'h A, Deugnier Y. Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients. Am J Clin Pathol 2001 116 2 263-270 (Pubitemid 33044332)
64. Bekri S, Gual P, Anty R et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 2006 131 3 788-796 (Pubitemid 44316823)
65. Lainé F, Deugnier Y. Increased expression of hepcidin in obese patients: impact on phenotypic expression of hemochromatosis and pathophysiology of dysmetabolic iron overload syndrome. Gastroenterology 2006 131 6 2028 (Pubitemid 44958531)
66. Lainé F, Jouannolle A M., Morcet J et al. Phenotypic expression in detected C282Y homozygous women depends on body mass index. J Hepatol 2005 43 6 1055-1059 (Pubitemid 41627992)
67. Bonkovsky H L., Lambrecht R W., Shan Y. Iron as a co-morbid factor in nonhemochromatotic liver disease. Alcohol 2003 30 2 137-144 (Pubitemid 37040860)
68. Kaji K, Nakanuma Y, Sasaki M, Unoura M, Kobayashi K, Nonomura A. Hemosiderin deposition in portal endothelial cells: a novel hepatic hemosiderosis frequent in chronic viral hepatitis B and C. Hum Pathol 1995 26 10 1080-1085
69. Boucher E, Bourienne A, Adams P, Turlin B, Brissot P, Deugnier Y. Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment. Gut 1997 41 1 115-120 (Pubitemid 27351650)
70. Fontana R J., Israel J, LeClair P et al. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology 2000 31 3 730-736 (Pubitemid 30118643)
71. Fujita N, Sugimoto R, Takeo M et al. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Mol Med 2007 13 1-2 97-104 (Pubitemid 46786838)
72. Hayashi H, Yano M, Fujita Y, Wakusawa S. Compound overload of copper and iron in patients with Wilson's disease. Med Mol Morphol 2006 39 3 121-126 (Pubitemid 44440460)
73. Alla V, Bonkovsky H L. Iron in nonhemochromatotic liver disorders. Semin Liver Dis 2005 25 4 461-472 (Pubitemid 41741262)
74. Cotler S J., Bronner M P., Press R D. et al. End-stage liver disease without hemochromatosis associated with elevated hepatic iron index. J Hepatol 1998 29 2 257-262 (Pubitemid 28352811)
75. Brissot P, Wright T L., Ma W L., Weisiger R A. Efficient clearance of non-transferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states. J Clin Invest 1985 76 4 1463-1470 (Pubitemid 16193695)
76. Détivaud L, Nemeth E, Boudjema K et al. Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood 2005 106 2 746-748 (Pubitemid 40981276)
77. Kijima H, Sawada T, Tomosugi N, Kubota K. Expression of hepcidin mRNA is uniformly suppressed in hepatocellular carcinoma. BMC Cancer 2008 8 167
78. Turlin B, Juguet F, Moirand R et al. Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver. Hepatology 1995 22 2 446-450
79. Ko C, Siddaiah N, Berger J et al. Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry. Liver Int 2007 27 10 1394-1401 (Pubitemid 350142254)
80. Nahon P, Sutton A, Rufat P et al. Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. Gastroenterology 2008 134 1 102-110 (Pubitemid 350309327)
81. Deugnier Y, Turlin B. Iron and hepatocellular carcinoma. J Gastroenterol Hepatol 2001 16 5 491-494 (Pubitemid 34188853)
82. Bottomley S S. Secondary iron overload disorders. Semin Hematol 1998 35 1 77-86 (Pubitemid 28047044)
83. Cappellini M D., Cohen A, Piga A et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006 107 9 3455-3462
84. Deugnier Y, Turlin B, Ropert M et al. Semi-quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade, ICL670) or deferoxamine in patients with transfusion-dependent anemia. Blood 2005 106 11 abstract #912
85. Deugnier Y, Turlin B, Ropert M et al. Improvement in liver pathology in patients with thalassemia treated with deferasirox for at least 3 years. Gastroenterology 2011 In press
86. Mirault T, Lucidarme D, Turlin B et al. Non-invasive assessment of liver fibrosis by transient elastography in post transfusional iron overload. Eur J Haematol 2008 80 4 337-340 (Pubitemid 351347574)
87. Walsh A, Dixon J L., Ramm G A. et al. The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis. Clin Gastroenterol Hepatol 2006 4 11 1403-1410 (Pubitemid 44716739)